theranostics
Vyriad Raises $29.5M in Extended Series B Financing
Vyriad is developing oncolytic viruses, which may treat a range of cancers alone or in combination with checkpoint inhibitors.
Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada
The first-in-human study is designed to assess both the gallium-68-labeled imaging agent and the lutetium-177-labeled therapeutic in five solid cancer types.
NCCN, SNMMI Update Guidelines to Expand PET Imaging Agents for Pluvicto Eligibility
The organizations said fluorine-18-based PET imaging can be used to screen mCRPC patients for Pluvicto in addition to the gallium-68-based agent noted on FDA labeling.
Novartis Pauses US Pluvicto Production Due to Possible Quality Issues
The news, which drove Novartis stock down on Thursday, comes about a month after the targeted radiopharmaceutical's FDA approval for metastatic prostate cancer.
Telix Pharmaceuticals Doses First Kidney Cancer Patient in Radiopharmaceutical Trial
The firm is evaluating its CA9-directed targeted radiopharmaceutical TLX250 with Opdivo for advanced clear-cell renal cell carcinoma patients.